Publications by authors named "Daniela Zackova"

Claim this Profile
P
Potential differences between real-life and randomized controlled trial populations in chronic myeloid leukemia.
Tomáš Horňák, Daniela Žáčková, Jiří Mayer

Ann Hematol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Prognostic Significance of Additional Chromosomal Abnormalities at Diagnosis of Chronic Myeloid Leukemia.
Jiří Mayer, Petra Čičátková, Lenka Kováčová, Marie Jarošová, Michal Karas

Am J Hematol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total psoriasis regression in a patient with chronic myeloid leukemia treated using nilotinib.
Tomáš Horňák, Daniela Žáčková, Jiří Mayer

Ann Hematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical efficacy and safety of first-line nilotinib or imatinib therapy in patients with chronic myeloid leukemia-Nationwide real life data.
Petra Belohlavkova, Daniela Zackova, Hana Klamova, Edgar Faber, Michal Karas

Cancer Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial.
Fabio Efficace, Francois-Xavier Mahon, Johan Richter, Alfonso Piciocchi, Marta Cipriani, Daniela Zackova

Leukemia· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes.
Maria Agustina Perusini, Daniela Žáčková, Taehyung Kim, Katia Pagnano, Carolina Pavlovsky

Blood Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
Annamaria Brioli, Elza Lomaia, Christian Fabisch, Tomasz Sacha, Hana Klamova, Daniela Zackova

Leukemia· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors.
Tomas Hornak, Jiri Mayer, Petra Cicatkova, Lukas Semerad, Anezka Kvetkova, Daniela Zackova

Am J Hematol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
Daniela Žáčková, Lukáš Semerád, Edgar Faber, Hana Klamová, Lukáš Stejskal

Leukemia· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
Katerina Machova Polakova, Ali Albeer, Vaclava Polivkova, Monika Krutska, Katerina Vlcanova, Daniela Zackova

Leukemia· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia.
Andrea Knight, Martin Piskacek, Michal Jurajda, Jirina Prochazkova, Zdenek Racil, Daniela Zackova

Cancer Immunol Immunother· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
Matthew Salmon, Helen E White, Hana Zizkova, Andrea Gottschalk, Eliska Motlova, Daniela Zackova

Leukemia· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI.
Johan Richter, Anna Lübking, Stina Söderlund, Kourosh Lotfi, Berit Markevärn

Leukemia· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow-up.
Marianna Romzova, Dagmar Smitalova, Jakub Hynst, Nikola Tom, Tomas Loja, Daniela Zackova

Br J Haematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of two CE-IVD tests for transcript monitoring of chronic myeloid leukemia patients.
Adam Folta, Tomas Jurcek, Blanka Kubesova, Daniela Zackova, Lukas Semerad

Leuk Lymphoma· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.
Daniela Zackova, Hana Klamova, Petra Belohlavkova, Lukas Stejskal, Tereza Necasova

Leuk Lymphoma· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signaling complex.
Tomas Gregor, Michaela Kunova Bosakova, Alexandru Nita, Sara P Abraham, Bohumil Fafilek, Daniela Zackova

Cell Mol Life Sci· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission.
Katerina Machova Polakova, Hana Zizkova, Jan Zuna, Eliska Motlova, Lenka Hovorkova, Daniela Zackova

Leukemia· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
Markus Pfirrmann, Richard E Clark, Witold Prejzner, Michael Lauseker, Michele Baccarani, Daniela Zackova

Leukemia· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Illumina-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia.
Marianna Romzova, Dagmar Smitalova, Nikola Tom, Tomas Jurcek, Martin Culen, Daniela Zackova

Br J Haematol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in CML patients - results from real-life prospective study.
Tomáš Horňák, Lukáš Semerád, Daniela Žáčková, Barbora Weinbergerová, Zuzana Šustková

Leuk Lymphoma· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.
Michael Lauseker, Katharina Bachl, Anna Turkina, Edgar Faber, Witold Prejzner, Daniela Zackova

Am J Hematol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.
Zdenek Racil, Eva Koritakova, Tomasz Sacha, Hana Klamova, Petra Belohlavkova, Daniela Zackova

Am J Hematol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients.
Petra Belohlavkova, Filip Vrbacky, Jaroslava Voglova, Zdenek Racil, Daniela Zackova

Arch Med Sci· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for Treatment-free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient-Physician Perspective.
Giuseppe Saglio, Giora Sharf, Antonio Almeida, Andrija Bogdanovic, Felice Bombaci, Daniela Zackova

Clin Lymphoma Myeloma Leuk· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis